RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $1.82 billion. The enterprise value is $1.70 billion.
Market Cap | 1.82B |
Enterprise Value | 1.70B |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, after market close.
Earnings Date | Aug 5, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
RxSight has 38.98 million shares outstanding. The number of shares has increased by 16.46% in one year.
Shares Outstanding | 38.98M |
Shares Change (YoY) | +16.46% |
Shares Change (QoQ) | +2.40% |
Owned by Insiders (%) | 5.25% |
Owned by Institutions (%) | 85.25% |
Float | 32.03M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 172.41 |
PS Ratio | 18.03 |
Forward PS | 12.35 |
PB Ratio | 11.12 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 16.81 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.20, with a Debt / Equity ratio of 0.02.
Current Ratio | 9.20 |
Quick Ratio | 8.05 |
Debt / Equity | 0.02 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -23.59 |
Financial Efficiency
Return on equity (ROE) is -27.70% and return on invested capital (ROIC) is -28.63%.
Return on Equity (ROE) | -27.70% |
Return on Assets (ROA) | -24.00% |
Return on Capital (ROIC) | -28.63% |
Revenue Per Employee | $270,324 |
Profits Per Employee | -$118,973 |
Employee Count | 374 |
Asset Turnover | 0.54 |
Inventory Turnover | 2.01 |
Taxes
In the past 12 months, RxSight has paid $29,000 in taxes.
Income Tax | 29,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.47% in the last 52 weeks. The beta is 1.20, so RxSight's price volatility has been higher than the market average.
Beta (5Y) | 1.20 |
52-Week Price Change | +43.47% |
50-Day Moving Average | 57.16 |
200-Day Moving Average | 45.72 |
Relative Strength Index (RSI) | 30.33 |
Average Volume (20 Days) | 658,175 |
Short Selling Information
The latest short interest is 1.85 million, so 4.74% of the outstanding shares have been sold short.
Short Interest | 1.85M |
Short Previous Month | 1.51M |
Short % of Shares Out | 4.74% |
Short % of Float | 5.77% |
Short Ratio (days to cover) | 4.13 |
Income Statement
In the last 12 months, RxSight had revenue of $101.10 million and -$44.50 million in losses. Loss per share was -$1.25.
Revenue | 101.10M |
Gross Profit | 64.09M |
Operating Income | -47.66M |
Pretax Income | -44.47M |
Net Income | -44.50M |
EBITDA | -38.28M |
EBIT | -42.66M |
Loss Per Share | -$1.25 |
Balance Sheet
The company has $126.07 million in cash and $2.52 million in debt, giving a net cash position of $123.54 million or $3.17 per share.
Cash & Cash Equivalents | 126.07M |
Total Debt | 2.52M |
Net Cash | 123.54M |
Net Cash Per Share | $3.17 |
Equity (Book Value) | 163.93M |
Book Value Per Share | 4.21 |
Working Capital | 150.23M |
Cash Flow
In the last 12 months, operating cash flow was -$33.14 million and capital expenditures -$6.03 million, giving a free cash flow of -$39.17 million.
Operating Cash Flow | -33.14M |
Capital Expenditures | -6.03M |
Free Cash Flow | -39.17M |
FCF Per Share | -$1.06 |
Margins
Gross margin is 63.39%, with operating and profit margins of -47.14% and -44.01%.
Gross Margin | 63.39% |
Operating Margin | -47.14% |
Pretax Margin | -43.98% |
Profit Margin | -44.01% |
EBITDA Margin | -37.86% |
EBIT Margin | -42.19% |
FCF Margin | -38.75% |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -16.46% |
Shareholder Yield | -16.46% |
Earnings Yield | -2.44% |
FCF Yield | -2.15% |
Analyst Forecast
The average price target for RxSight is $65.14, which is 39.28% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $65.14 |
Price Target Difference | 39.28% |
Analyst Consensus | Strong Buy |
Analyst Count | 7 |
Revenue Growth Forecast (5Y) | 27.01% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of 53.02 and a Piotroski F-Score of 4.
Altman Z-Score | 53.02 |
Piotroski F-Score | 4 |